Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1, open-label, single-dose, within-cohort randomized, 2-way crossover study to evaluate the PK of orally administered PF-06650833 modified release tablets under fasted and high fat meal fed conditions in healthy subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects

NCT02485769

Healthy

COMPLETED PHASE1

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

NCT03871439

Healthy

COMPLETED PHASE1

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

NCT03492697

Healthy Subjects

COMPLETED PHASE1

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

NCT02184429

Healthy

COMPLETED PHASE1

A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects

NCT02539550

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is the third study of PF-06650833. The goals of the study are to assess the PK in healthy subjects of single doses of modified release (MR) tablets of PF-06650833 when orally administered under fasting and high fat meal fed conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

<=400mg Modified Release Tablets, Fasted

Up to 400 mg PF-06650833 modified release tablets administered under fasted conditions

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

Up to 400mg modified release tablets administered under fasted conditions

100mg Modified Release Tablets, Fasted

100 mg PF-06650833 modified release tablets administered under fasted conditions

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

100mg modified release tablet administered under fasted conditions

20mg Modified Release Tablets, Fasted

20 mg PF-06650833 modified release tablets administered under fasted conditions

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

20mg modified release tablet administered under fasted conditions

<= 400mg Modified Release Tablets, Fed

Up to 400 mg PF-06650833 modified release tablets administered with high fat meal food intake

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

Up to 400mg modified release tablets administered with high fat meal food intake

100mg Modifed Release Tablets, Fed

100 mg PF-06650833 modified release tablets administered with high fat meal food intake

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

100mg modified released tablet administered with high fat meal food intake

20mg Modified Release Tablets, Fed

20 mg PF-06650833 modified release tablets administered with high fat meal food intake

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

20 mg modified release tablet administered with high fat meal food intake

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-06650833

Up to 400mg modified release tablets administered under fasted conditions

Intervention Type DRUG

PF-06650833

100mg modified release tablet administered under fasted conditions

Intervention Type DRUG

PF-06650833

20mg modified release tablet administered under fasted conditions

Intervention Type DRUG

PF-06650833

Up to 400mg modified release tablets administered with high fat meal food intake

Intervention Type DRUG

PF-06650833

100mg modified released tablet administered with high fat meal food intake

Intervention Type DRUG

PF-06650833

20 mg modified release tablet administered with high fat meal food intake

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy female subjects of non childbearing potential and/or male subjects, between the ages of 18 and 55 years
2. BMI of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).
3. Personally signed and dated Informed Consent
4. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

1. Clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
2. Any condition possibly affecting drug absorption
3. Positive urine drug screen.
4. Heavy smokers
5. History of regular heavy alcohol consumption within 6 months of Screening.
6. Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives
7. Screening supine blood pressure \<=100 mm Hg (systolic) or\<=50 mm Hg (diastolic) or\>=140 mm Hg (systolic) or \>=90 mm Hg (diastolic), following at least 5 minutes of supine rest.
8. Screening pulse (HR) \>100 bpm after at least 5 minutes of rest.
9. Single supine 12 lead ECG demonstrating QTc \>450 msec or a QRS interval \>120 msec at Screening.
10. Abnormal chest X ray
11. History of TB or active or latent or inadequately treated infection, positive Quantiferon TB test.
12. History of hepatitis or positive testing for human HIV,HepBsAg, HepBc Ab or HCVAb
13. Any medical history of disease \[ie, Gilbert's disease\] that has the potential to cause a rise in total bilirubin over the ULN
14. Clinical laboratory abnormalities including:

* Creatine kinase \>1.2 X ULN;
* CK MB \> ULN;
* Serum myoglobin \>1.2 X ULN;
* Cardiac Troponin I (cTn I) \> ULN of the laboratory reference range;
* Serum aspartate transaminase (AST) or alanine transaminase (ALT) \>=2 x ULN, total serum bilirubin \>=1.5 mg/dL;
* Subjects with benign ethnic neutropenia;
* Hemoglobin \<=14 gm/dl (males) and \<=13 gm/dL (females).
15. Nursing female subjects; male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for 28 days after the last dose of investigational product or longer based upon the compound's half life characteristics.
16. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product until discharge from the study at the end of Period 2.

Herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of investigational product. Acetaminophen/paracetamol should not be used. As an exception, ibuprofen may be used at doses of 200 to 400 mg orally every 6 hours as needed for up to 3 of 7 consecutive days.
17. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
18. History of sensitivity to heparin or heparin induced thrombocytopenia.
19. History of cancer (other than treated basal cell and squamous cell carcinoma of the skin) in the previous 5 years.
20. Previous exposure to PF 06650833.
21. Unwilling or unable to comply with the Lifestyle guidelines
22. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees directly involved in the conduct of the study.
23. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes